Recent share performance and business context

With no single headline event driving Rhythm Pharmaceuticals (RYTM) today, the stock’s recent moves and fundamentals are in focus as investors weigh share price performance against the company’s rare disease portfolio.

The recent 1 day share price return of a 2.45% decline and 90 day share price return of a 19.9% decline contrast with a 1 year total shareholder return of 28.71% and a very large 3 year total shareholder return, which together may indicate long term momentum despite recent weakness.

If you are looking beyond a single rare disease name and want to see what else is moving in related areas, this may be a useful moment to scan 32 healthcare AI stocks

So, with Rhythm Pharmaceuticals trading at a discount to both analyst targets and some intrinsic estimates despite recent share price declines, are you looking at an undervalued rare disease story or a stock where the market already reflects future growth?

Most Popular Narrative: 40.3% Undervalued

Rhythm Pharmaceuticals last closed at $82.12, while the most widely followed narrative anchors fair value at $137.67, putting the focus squarely on what needs to go right to bridge that gap.

Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader Willi syndrome, alongside expansion into younger age groups, are set to materially grow Rhythm's commercial opportunity and topline over the next several years.

Curious what kind of revenue ramp, margin shift and future earnings multiple are baked into that fair value, and how tightly those assumptions are tied to one drug and a handful of late stage trials.

Result: Fair Value of $137.67 (UNDERVALUED)

However, heavy ongoing losses and reliance on setmelanotide mean any clinical, regulatory or reimbursement setback could quickly challenge that 40.3% undervalued narrative.

Another View on Valuation

While the SWS DCF model points to a very large gap between the current $82.12 share price and an estimated fair value of $419.66, Rhythm Pharmaceuticals also trades on a high P/S ratio of 29.6x versus a fair ratio of 17.1x and a US Biotechs average of 10.8x. This raises the question of whether growth expectations or downside risk are being mispriced.

For a closer look at how that sales based valuation compares with fundamentals, including how much room there might be for the P/S ratio to move toward the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

After weighing bullish and cautious signals, it helps to see the numbers in context and act before sentiment shifts too far. To understand what has investors optimistic and to judge those potential rewards for yourself, check out the 3 key rewards

Looking for more investment ideas?

If you stop with just one stock, you risk missing out on other opportunities that better fit your goals, risk comfort and income needs.

• Target value oriented opportunities by scanning companies highlighted in the 53 high quality undervalued stocks so you can compare pricing against fundamentals in one place.
• Prioritise resilience and capital preservation by reviewing the 73 resilient stocks with low risk scores to spot businesses that align with a more conservative approach.
• Chase growth potential off the beaten path by checking the screener containing 25 high quality undiscovered gems and see which names are attracting attention before they become crowded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.